

Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024

https://marketpublishers.com/r/FBFED4B91C0EN.html

Date: August 2017

Pages: 120

Price: US\$ 1,150.00 (Single User License)

ID: FBFED4B91C0EN

Abstracts

United States flu vaccine market is expected to reach nearly US\$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.

Long-term Growth Projection and Development:

Sanofi to Acquire Protein Sciences Corporation

It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024.

Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season

It is projected that GSK flu vaccine sales value will reach around US\$ 1.5 Billion by 2024

BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine

"Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024" provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in–depth analysis of the flu



vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.

Key Topics Covered in the Report

Market Overview: United States Flu Vaccine Market (2010 - 2024)

United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)

United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification

Reimbursement & Regulatory System in the US Flu Vaccine Market

Mergers, Acquisitions, Key Agreements & Collaborations

Promising Flu Vaccine in Clinical Development

Flu Vaccine Clinical Trial Insights by Phase, Company & Country

Key Drivers and Inhibitors of the US Flu Vaccine Market

Key Companies Analysis

Major Flu Vaccines Covered Under This Report Are:

Fluzone High-Dose



Key

	Fluzone Quadrivalent
	Intradermal (ID) Trivalent
	Vaxigrip
	Fluarix Quadrivalent
	Flulaval Quadrivalent
	Flucelvax Quadrivalent
	Afluria Quadrivalent
	Agrippal
	Fluad
	Fluvirin
	Fluvax
Companies Covered in This Report:	
	Seqirus
	Sanofi Pasteur
	GlaxoSmithKline(GSK)



Contents

- 1. EXECUTIVE SUMMARY
- 2. MARKET OVERVIEW: UNITED STATES FLU VACCINE MARKET (2010 2024)
- 3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH FLU VACCINE (2010 2024)
- 3.1 Number of Children Vaccinated
- 3.2 Number of Adults Vaccinated
- 4. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES FLU VACCINE MARKET
- 4.1 Market Drivers
- 4.2 Market Inhibitors
- 5. UNITED STATES FLU VACCINE PRODUCTION, PRICE, CONSUMPTION, SUPPLY, DISTRIBUTION, DEMAND AND SPECIFICATION
- 5.1 Flu Vaccine Price Trends
 - 5.1.1 Pediatric Flu Vaccine Price Trends
 - 5.1.2 Adult Flu Vaccine Price Trends
- 5.2 United States Flu Vaccine Production, Supply, and Allocation (By Companies)
- 5.3 United States Flu Vaccine Distribution & Demand
- 5.4 Flu Vaccine Effectiveness
- 5.5 Managing Flu with Rapid Diagnostic Testing
- 5.6 Distribution Method of Flu Vaccination
- 6. UNITED STATES FLU VACCINE MARKET REIMBURSEMENT & REGULATORY SYSTEM
- 6.1 Reimbursement System
- 6.2 Regulation System
- 7. MARKET DYNAMICS MERGERS, ACQUISITIONS, KEY AGREEMENTS & COLLABORATIONS



- 7.1 Merger & Acquisitions
- 7.2 Collaboration Deal
- 7.3 Licensing, Exclusive & Distribution Agreement Deal
 - 7.3.1 Licensing Agreement
 - 7.3.2 Exclusive Agreement
- 7.3.3 Distribution Agreement

8. FLU VACCINE - PROMISING VACCINE IN CLINICAL DEVELOPMENT

- 8.1 Quadrivalent Seasonal Influenza VLP Vaccine
- 8.2 VN -
- 8.3 Seasonal Influenza VLP Vaccine
- 8.4 M-001

9. FLU VACCINE – CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY

- 9.1 Year 2017
- 9.2 Year 2016

10. KEY COMPANIES ANALYSIS

- 10.1 Sanofi Pasteur
 - 10.1.1 Business Overview
 - 10.1.2 Flu Vaccine Outlook
 - 10.1.2.1 Fluzone High-Dose Vaccine
 - 10.1.2.2 Fluzone Quadrivalent Vaccine
 - 10.1.2.3 Intradermal (ID) Trivalent Flu Vaccine
 - 10.1.2.4 Vaxigrip Vaccine
 - 10.1.3 Flu Vaccine Sales Analysis & Forecast (2011 2024)
 - 10.1.4 Flu Vaccine Latest Development and Trends
- 10.2 GlaxoSmithKline (GSK)
 - 10.2.1 Business Overview
 - 10.2.2 Flu Vaccine Outlook
 - 10.2.2.1 Fluarix Quadrivalent
 - 10.2.2.2 Flulaval Quadrivalent
 - 10.2.3 Flu Vaccine Sales Analysis & Forecast (2011 2024)
 - 10.2.4 Flu Vaccine Latest Development & Trends
- 10.3 Segirus (CSL Limited)



- 10.3.1 Business Overview
- 10.3.2 Flu Vaccine Outlook
 - 10.3.2.1 Flucelvax Quadrivalent
 - 10.3.2.2 Afluria Quadrivalent
 - 10.3.2.3 Agrippal
 - 10.3.2.4 Fluad
 - 10.3.2.5 Fluvirin
 - 10.3.2.6 Fluvax
- 10.3.3 Flu Vaccine Latest Development & Trends



List Of Tables

LIST OF TABLES

- Table 5–2: United States Pediatric Flu Vaccine Price, 2017 2018
- Table 5-3: United States Adult Flu Vaccine Price, 2017 2018
- Table 5–4: United States Flu Vaccine Production, Supply, and Allocation
- Table 5-5: Total Percentage of Flu Vaccines Released by Week, 2016 2017
- Table 5-6: Total Percentage of Flu Vaccines Released by Week, 2015 2016
- Table 5-7: Total Percentage of Flu Vaccines Released by Week, 2014 2015
- Table 5–8: Adjusted Vaccine Effectiveness Estimates for Flu Seasons, 2005 2016
- Table 5-9: Influenza Virus Testing Methods
- Table 5-10: Distribution of Flu Vaccination
- Table 6–1: United States Simplified Regulatory Pathway from Preclinical to the
- Marketing Authorization
- Table 7-1: Flu Vaccine Market Merger & Acquisitions (Million US\$),2003 2017
- Table 7–2: Flu Vaccine Market Collaborations Deal, 2007 2017
- Table 7-3: Flu Vaccine Market Licensing Agreement, 2007 2016
- Table 7–4: Flu Vaccine Market Exclusive Agreement, 2009 2016
- Table 7–5: Flu Vaccine Market Distribution Agreement, 2005 2016



List Of Figures

LIST OF FIGURES

Figure 2 1: United States – Flu Vaccine Market (Million US\$),2010 – 2016

Figure 2 2: United States - Forecast for Flu Vaccine Market (Million US\$),2017 - 2024

Figure 3 1: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2016

Figure 3 2: United States – Forecast for Total Number of Persons

Vaccinated(Thousand), 2017 - 2024

Figure 3 3: United States – Number of Children Vaccinated(Thousand), 2010 – 2016

Figure 3 4: United States – Forecast for Number of Children

Vaccinated(Thousand),2017 - 2024

Figure 3 5: United States – Number of Adults Vaccinated(Thousand),2010 – 2016

Figure 3 6: United States – Forecast for Number of Adults Vaccinated(Thousand),2017 – 2024

Figure 5 1: United States – Flu Vaccine Doses Distributed, By Season(Million),2010 – 2017

Figure 10 1: Sanofi Pasteur – Flu Vaccine Net Sales (Million US\$),2011 – 2016

Figure 10 2: Sanofi Pasteur – Forecast for Flu Vaccine Net Sales (Million US\$),2017 – 2024

Figure 10 3: GSK – Flu Vaccine Net Sales (Million US\$),2011 – 2016

Figure 10 4: GSK - Forecast for Flu Vaccine Net Sales (Million US\$),2017 - 2024



I would like to order

Product name: Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis,

Market Forecast 2017-2024

Product link: https://marketpublishers.com/r/FBFED4B91C0EN.html

Price: US\$ 1,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/FBFED4B91C0EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

